オプションチェーンは、Phio Pharmaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Phio Pharmaの市場センチメントを評価します。.

Phio Pharma (NASDAQ:PHIO) 株価情報, オプションチェーン

Phio Pharma

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharmaceuticals Corp

Evercore ISI Group analyst Steve Sakwa maintains Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) with a In-Line and lowers the price target from $24 to $23.

News

Price Target

Analyst Ratings

Evercore ISI Group Maintains In-Line on Kimco Realty, Lowers Price Target to $23

WIIM

CREV

Carbon Revolution shares are trading higher after the company announced it has reached an agreement with OIC for a further $25 million in financing to support the ongoing liquidity of the business.

Evercore ISI Group analyst Samir Khanal maintains Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) with a In-Line and lowers the price target from $32 to $31.

Evercore ISI Group Maintains In-Line on Brixmor Property Group, Lowers Price Target to $31

Dollar Gen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) short percent of float has risen 14.56% since its last report. The company recently reported that it has 8.27 million shares sold short, which is 4.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dollar Gen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735047921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dollar Gen has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Dollar Gen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dollar Gen's peer group average for short interest as a percentage of float is 3.44%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Dollar Gen?

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has fallen 9.01% since its last report. The company recently reported that it has 3.39 million shares sold short, which is 3.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735047916_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 4.97%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ALNY

How Is The Market Feeling About Alnylam Pharmaceuticals?

Dollar Tree's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NYSE">DLTR</a>) short percent of float has fallen 22.06% since its last report. The company recently reported that it has 9.53 million shares sold short, which is 5.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dollar Tree Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735047911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dollar Tree has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dollar Tree's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dollar Tree's peer group average for short interest as a percentage of float is 3.30%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

DLTR

Looking Into Dollar Tree's Recent Short Interest

As of Dec. 24, 2024, two stocks in the financial sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 7</a>0, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">LexinFintech Holdings Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>)</h3>
<ul>
<li>On Nov. 25, LexinFintech announced its board approved an amendment for a dividend policy to increase the payout ratio. Also, the company reported third-quarter financial results. The company's stock surged around 76% over the past month and has a <a href="https://www.benzinga.com/quote/LX">52-week high of $6.28</a>.</li>
<li>RSI Value: 70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>LX Price Action: Shares of LexinFintech closed at $5.99 on Monday.</li>
</ul>
<h3 class="wp-block-heading">AppTech Payments Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APCX#NASDAQ">APCX</a>)</h3>
<ul>
<li>On Dec. 17, AppTech Payments announced it received a $5 million investment from AFIOS Partners and is restructuring its board by appointing three new directors. AppTech&#8217;s Chairman, Luke D&#8217;Angelo stated, &#8220;We genuinely appreciate our outgoing board members&#8217; unwavering dedication to AppTech. We are excited to work with our new AFIOS partners, who are clearly focused on near- and long-term value creation. &#8221; The company's stock gained around 86% over the past five days and <a href="https://www.benzinga.com/quote/APCX">has a 52-week high</a> of $2.30.</li>
<li>RSI Value: 73</li>
<li>APCX Price Action: Shares of AppTech Payments closed at $0.84 on Monday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

Pre-Market Outlook

Markets

APCX

Top 2 Financial Stocks That May Keep You Up At Night This Month

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/12/23/final-trades-zoom-video-lockheed-martin-and-the-iwd.html">Halftime Report Final Trades</a>,&#8221; Joseph M. Terranova of Virtus Investment Partners said Zoom Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is one of his favorite <a href="https://www.benzinga.com/news/management/24/11/42176089/zoom-communications-q3-earnings-revenue-beat-eps-beat-online-churn-hits-all-time-low-company-name-change-and-more">stocks to own in 2025</a>.
On Nov. 25, Zoom reported third-quarter revenue of $1.18 billion, beating the consensus estimate of $1.16 billion. The communications company reported third-quarter adjusted earnings of $1.38 per share, beating analyst estimates of $1.31 per share.
On Dec. 19, Jefferies analyst Samad Samana upgraded Zoom Communications from Hold to Buy and raised the price target from $85 to $100.
Jim Lebenthal of Cerity Partners named Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) as his final trade.
On Dec. 16, Lockheed Martin revealed the launch of the seventh Lockheed Martin-designed and built Global Positioning System (GPS) III satellite, GPS III SV07, at 7:52 p.m. ET. The GPS III SV07 spacecraft, built at Lockheed Martin's Littleton, Colorado, facility, was transported by ground to its Florida launch site after its usual military aircraft was reassigned <a href="https://www.benzinga.com/24/12/42527692/mission-accomplished-lockheed-martins-gps-iii-sv07-successfully-deployed">for hurricane relief efforts.</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Rob Sechan of NewEdge Wealth picked iShares Russell 1000 Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWD#NYSE">IWD</a>).
Price Action:
<ul>
<li>Zoom shares fell by 0.4% to close at $85.27 on Monday.</li>
<li>Lockheed Martin shares fell 0.5% to close at $486.49 during Monday's session.</li>
<li>iShares Russell 1000 Value ETF rose 0.2% on Monday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Long Ideas

Media

Zoom Communications, Lockheed Martin And More: CNBC's 'Final Trades'

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company's near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology.
Under the terms of the agreements, a deferred consideration payment of $5 million related to the acquisition of the biosensor assets of Waveform Technologies has been extended to November 2025, offering the Company greater financial flexibility. In addition, further additional liquidity in the amount of approximately $5.5 million has been provided to Trinity Biotech through a combination of cash and payment-in-kind interest, strengthening liquidity during this pivotal period of transformation. As part of the agreement, Trinity Biotech has granted Perceptive Advisors 1.5 million additional warrants to purchase the Company's ADS, and repriced its existing ADS warrants at an exercise price of $0.80 per ADS, reinforcing the ongoing partnership between the two entities.

Offerings

Management

TRIB

Trinity Biotech Amends Credit Agreement With Perceptive Advisors To Boost Liquidity And Support Transformation Plan; Secures $5.5M In Additional Funding, Extends $5M Payment To 2025, And Issues 1.5M New Warrants At $0.80 Exercise Price

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Equity Commonwealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQC#NYSE">EQC</a>)</h3>
<ul>
<li>On Nov. 26, Equity Commonwealth completed the sale of 1250 H Street. The company's stock fell around 91% over the past month and has a <a href="https://www.benzinga.com/quote/EQC">52-week low of $1.40</a>.</li>
<li>RSI Value: 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>EQC Price Action: Shares of Equity Commonwealth fell 1.7% to close at $1.74 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1">latest EQC news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="878" height="782" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083110/image-196.png" alt="" class="wp-image-705981" style="width:670px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083110/image-196.png 878w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083110/image-196-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083110/image-196-768x684.png 768w" sizes="(max-width: 878px) 100vw, 878px" /></a></figure>
<h3 class="wp-block-heading">Wheeler Real Estate Investment Trust Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)</h3>
<ul>
<li>On Nov. 15, Wheeler Real Estate Investment Trust announced a 1-for-2 reverse stock split. The company's stock fell around 52% over the past month and &lt;a href=&#8221;https://www.benzinga.com/quote/WHLR&#8221;&gt;&lt;em&gt; has a 52-week low &lt;/em&gt;&lt;/a&gt; of $3.75.</li>
<li>RSI Value: 24</li>
<li>WHLR Price Action: Shares of Wheeler Real Estate Investment Trust closed at $4.05 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1">trend in WHLR stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="921" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083138/image-197.png" alt="" class="wp-image-705982" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083138/image-197.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083138/image-197-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083138/image-197-768x685.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
<h3 class="wp-block-heading">LXP Industrial Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXP#NYSE">LXP</a>)</h3>
<ul>
<li>On Nov. 6, LXP Industrial Trust reported better-than-expected third-quarter financial results. T. Wilson Eglin, Chairman and Chief Executive Officer of LXP, commented &#8220;We posted strong third-quarter results with same-store NOI growth of 5.4% driven by 39.1% cash rental increases on second generation leases completed through September 30, 2024. We made progress on development leasing, executing a five-year lease at our 250,000 square foot development project in Columbus with a development yield of 8.5% and 3.5% annual rental increases." The company's stock fell around 12% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/LXP">low of $8.08</a>.</li>
<li>RSI Value: 29</li>
<li>LXP Price Action: Shares of LXP Industrial Trust fell 0.5% to close at $8.28 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1">breakout in LXP shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="877" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083244/image-198.png" alt="" class="wp-image-705983" style="width:697px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083244/image-198.png 877w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083244/image-198-300x289.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24083244/image-198-768x740.png 768w" sizes="(max-width: 877px) 100vw, 877px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

WHLR

Top 3 Real Estate Stocks Which Could Rescue Your Portfolio For Q4

Offering Real-Time Availability, Transparent Pricing, And Seamless Trip Management; Updates CharterGPT App With Carbon Tracking, Push Notifications, And Deep Linking.

JTAI

Jet.AI Launches "Ava," An Agentic AI Model For Private Jet Booking

Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of 8,065,210 shares of its common stock and an equal number of five-year warrants, both priced at $0.23 per share, in a private placement for aggregate gross proceeds of $1.85 million before deducting offering expenses and fees (the "Private Placement"). The warrants, if exercised, will result in an additional $1.85 million in proceeds to Carmell. The Private Placement was priced at a slight premium to the CTCX closing price on December 23, 2024.
Said Mr. Rajiv Shukla, Chairman of Carmell, "We are happy to announce an additional round of investment from existing and new investors to support the continued commercial build out of our revolutionary bio-aesthetics product pipeline."

CTCX

Carmell Enters Securities Purchase Agreement With New And Existing Investors For The Issuance And Sale Of 8,065,210 Shares Of Its Common Stock And An Equal Number Of 5-Year Warrants, Both Priced At $0.23 Per Share, In A Private Placement For Aggregate Gross Proceeds Of $1.85M

NANO Nuclear acquires Micro Modular Reactor (MMR&#xAE;) and Pylon technologies, including all associated patents, through a Chapter 11 bankruptcy auction
New York, N.Y., Dec. 24, 2024 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) ("NANO Nuclear" or "the Company"), a leading advanced nuclear energy and technology company focused on developing portable, clean energy solutions, today announced that it has executed a definitive agreement to acquire select nuclear energy technology assets from Ultra Safe Nuclear Corporation and certain of its subsidiaries (collectively, "USNC").
The acquired assets include USNC's patented Micro Modular Reactor (MMR&#xAE;) system, along with all associated patents and other intellectual property rights, as well as its Pylon reactor technology and related intellectual property, and certain demonstration project partnerships related to the MMR system. The assets are being acquired for $8.5 million in cash through an auction process conducted pursuant to Section 363 of the U.S. Bankruptcy Code in connection with USNC's pending Chapter 11 bankruptcy proceedings. On December 18, 2024, the United States Bankruptcy Court for the District of Delaware, the Bankruptcy Court overseeing USNC's chapter 11 case, conducted a hearing and approved the transaction. The closing of the acquisition is expected to occur in the near future subject to satisfaction of customary closing conditions in a bankruptcy proceeding.

NANO Nuclear Energy Enters Into Agreement To Acquire Ultra Safe Nuclear Corp.'s Patented Micro Modular Reactor MMR And Pylon Space Reactors For $8.5M Along With Worldwide Demonstration Partnerships

In a brief but dramatic Christmas Eve disruption, American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) grounded all flights across the United States on Tuesday due to <a href="https://www.benzinga.com/markets/equities/24/12/42665923/is-stock-market-open-on-christmas-eve-2024-a-quick-guide-for-market-hours-banks-and-whats-closed-for-santa-claus">a temporary technical outage</a>. 
The issue was resolved by 7:50 a.m. ET, with the carrier restoring operations and addressing disruptions caused by the nationwide halt.
<h3 class="wp-block-heading">Flights Resume After Hours Of Uncertainty</h3>
An hour earlier, the Federal Aviation Administration issued an advisory stating that the carrier had halted all flights across the country, Reuters reports.
Passengers shared their frustration on X before the issue was resolved, with one flyer <a href="https://x.com/SACKsonville17/status/1871513983683067982">reporting</a>, "I just heard from the gate crew that there's a massive system outage and they can't scan boarding passes.&#8221;
The FAA's Air Traffic Control System Command Center later issued an update lifting the nationwide <a href="https://www.fly.faa.gov/adv/adv_otherdis.jsp?advn=26&amp;adv_date=12242024&amp;facId=DCC/DCC&amp;title=AAL+GROUND+STOP+CANCELLATION&amp;titleDate=12/24/24">groundstop </a>for American Airlines.
<h3 class="wp-block-heading">Airlines Briefly Recover Losses</h3>
Investors were quick to react. American Airlines stock initially plunged over 3% in premarket trading but bounced back, erasing all losses after systems were restored.
A benchmark of airlines stocks, as represented by the U.S. Global Jets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JETS#NYSE">JETS</a>), was 0.6% lower by 8:05 a.m. in New York.
Shares of United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) and Delta Air Lines Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) were both 0.2% higher. Alaska Air Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) was also up 0.2%, while Southwest Airlines Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) was unchanged. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42660092/microstrategy-sinks-after-nasdaq-100-inclusion-bitcoin-bet-under-fire">MicroStrategy Sinks After Nasdaq 100 Inclusion: Bitcoin Bet Under Fire?</a></li>
</ul>
Photo: Nate Hovee/Shutterstock.com

Equities

Large Cap

Sector ETFs

ETFs

JETS

American Airlines Lifts Christmas Eve Grounding, Shares Bounce Back

Cantor Fitzgerald analyst Ross Osborn reiterates AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) with a Overweight and maintains $21 price target.

Reiteration

RCEL

Cantor Fitzgerald Reiterates Overweight on AVITA Medical, Maintains $21 Price Target

Railroads (AAR), with its Technology Roadmap Program managed by MxV Rail
Ra'anana, Israel, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSN#NASDAQ">RVSN</a>) (the "Company"), a technology company at the forefront of revolutionizing railway safety and the data-related market, today announced it has joined MxV Rail's Technology Roadmap Program, a distinguished body responsible for formulating minimum interoperable requirements and supporting development of systems to improve operating safety and efficiency of rail operations in North America.
By joining the MxV Rail's Technology Roadmap Program, Rail Vision will contribute to the development of interoperable requirements, positioning itself as a pivotal player in the evolution of rail technology in the U.S. The involvement aligns Rail Vision with influential stakeholders, including Class 1 U.S. rail operators, and enhances its visibility among potential customers seeking innovative safety and automation solutions.
The TCCO committee operates under the auspices of the American Association of Railroads (AAR), with its Technology Roadmap Program managed by MxV Rail, a subsidiary of the AAR. MxV Rail is a renowned entity dedicated to conducting railroad equipment testing and providing training for U.S. member railroads, ensuring compliance with emerging federal standards and advancing rail safety.

RVSN

Rail Vision Joins MxV Rail's Technology Roadmap Program To Improve Safety And Efficiency Of Rail Operations In North America

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) fell sharply in today's pre-market trading after reporting <a href="https://www.benzinga.com/quote/LMNR/news">fourth-quarter results.</a>
Limoneira posted an adjusted net loss of $1.6 million, or 9 cents per share, versus a year-ago loss of $2.6 million, or 15 cents per share. Its total net revenue rose to $43.9 million from $41.4 million in the year-ago quarter.
Limoneira shares fell 2.6% to $26.12 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Tutor Perini Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) dipped 12.1% to $22.01 in pre-market trading.</li>
<li>Astria Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) fell 11.8% to $8.40 in pre-market trading.</li>
<li>Jiayin Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) shares fell 7.5% to $5.95 in pre-market trading. Jiayin Group, last week, announced the purchase of commercial property located in Shanghai, China for total cash consideration of RMB1.35 billion.</li>
<li>AngioDynamics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) dipped 7.3% to $8.21 in pre-market trading. AngioDynamics will report financial results for the second quarter of fiscal year before the opening bell on Wednesday, Jan. 8, 2025.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) fell 5.2% to $20.51 in pre-market trading.</li>
<li>ADS-TEC Energy PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSE#NASDAQ">ADSE</a>) shares fell 3% to $13.70 in pre-market trading.</li>
<li>Vinci Partners Investments Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) fell 2.9% to $9.57 in pre-market trading.</li>
<li>Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) declined 2.4% to $14.91 in pre-market trading.</li>
<li>Turtle Beach Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEAR#NASDAQ">HEAR</a>) declined 2.3% to $15.60 in pre-market trading.</li>
<li>Valhi, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) fell 2% to $21.30 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

Movers

ADSE

ANGO

ATXS

BASE

HEAR

JFIN

LMNR

PAHC

VINP

Limoneira And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Avita Medical shares are trading higher after D. Boral Capital initiated coverage on the stock with a Buy rating and announced a $25 price target.

The chief business officer and the chief insurance officer of the insurance technology company Lemonade Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) sold their shares in the company on Dec. 3, as per the SEC filings. The company&#8217;s technical analysis shows that the stock is under short-term pressure.
What Happened: John Sheldon Peters sold 1,790 shares of the company worth $81,445, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. After the transaction, the chief insurance officer was left with 88,493 shares of the company. He diluted 1.98% of his ownership after the trade.
On the other hand, the chief business officer Maya Prosor sold 304 shares, worth a total of $13,832, as per <a href="http://pro.benzinga.com">Benzinga </a>Pro. After the trade, he directly owns 8,684 company shares and 29,286 shares indirectly via Cohen Holdings, LLC. Prosor&#8217;s sale was conducted to cover tax withholding obligations and it wasn&#8217;t a discretionary decision.
See Also: <a href="https://www.benzinga.com/24/12/42640560/japan-cannot-happen-here-was-common-refrain-20-years-ago-in-the-west-mohammed-el-erian-says-as-tokyo-climbs-out-of-the-hole-this-country-looks-at-risk-of-falling-in">Mohammed El Erian Says This Country Faces Japan-Style Economic Risk Even As Tokyo Rebounds</a>
Why It Matters: From a technical perspective, the analysis of daily moving averages indicates that the stock may be under pressure in the short term.
The stock ended at $39.90 apiece on Monday. This was below its eight and 20-day simple moving averages, of $40.95 and $44.42, respectively. As per Benzinga Pro data, its current stock price was higher than the 50-day moving average of $33.92 and its 200-day moving average of $21.50.
This implies that it could still be in a long-term uptrend while it is testing fresh support levels near the average value.
On the other hand, the relative strength index of 49.22 suggests the stock is in a neutral zone and is neither overbought nor oversold.
<figure class="wp-block-image size-large"><a href="http://pro.benzinga.com"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24075141/Lemonade-Chart-1024x576.png" alt="" class="wp-image-705897" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24075141/Lemonade-Chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24075141/Lemonade-Chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24075141/Lemonade-Chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24075141/Lemonade-Chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24075141/Lemonade-Chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Price Action: Shares of Lemonade are up 134.15% on a year-to-date basis, outperforming the NYSE Composite, which was up 14.05% in the same period. However, Lemonade has fallen by 21.80% over the last month.
About 12 analysts tracked by <a href="https://www.benzinga.com/quote/LMND/analyst-ratings">Benzinga </a>have a consensus &#8216;sell&#8217; rating on the stock with a price target of $29.18 per share. The highest price target was $60 issued by JPMorgan on Nov. 22 and the low is $12 issued by BofA Securities on May 4, 2023.
The three most recent analyst ratings have seen a target upgrade by JMP Securities, BMO Capital, and Piper Sandler, however, it still implies a 0.58% downside for LMND.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/LMND/analyst-ratings"><img loading="lazy" decoding="async" width="945" height="358" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24075052/LMND-ANR.png" alt="" class="wp-image-705895" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24075052/LMND-ANR.png 945w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24075052/LMND-ANR-300x114.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24075052/LMND-ANR-768x291.png 768w" sizes="(max-width: 945px) 100vw, 945px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42667093/microstrategy-etfs-face-tracking-error-because-of-volatility-here-are-the-potential-risks-investors-face">MicroStrategy ETFs Face Tracking Error Because Of Volatility: Here Are The Potential Risks Investors Face</a></li>
</ul>
Image Via Shutterstock

Technicals

LMND

Insurance-Tech Company Lemonade Insiders Offload Shares: Technical Analysis Shows Short-Term Bullish Trends

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">238.64</td>
<td align="right">0.57</td>
<td align="right">0.23</td>
<td>3.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.22</td>
<td align="right">0.16</td>
<td align="right">0.21</td>
<td>622</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">84.08</td>
<td align="right">0.15</td>
<td align="right">0.17</td>
<td>8.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">138.90</td>
<td align="right">0.15</td>
<td align="right">0.10</td>
<td>3.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.45</td>
<td align="right">0.03</td>
<td align="right">0.06</td>
<td>10.1K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">228.96</td>
<td align="right">-0.21</td>
<td align="right">-0.1</td>
<td align="right">180</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For December 24, 2024

Warning: PHIO is at high risk of performing badly

Phio Pharmaceuticals GAAP EPS of -$1.54 beats by $2.60

PHIO

Press Releases

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Comments

Phio Pharma

Phio Pharma (PHIO) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル